Actively Recruiting
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Led by Pfizer · Updated on 2026-03-18
16
Participants Needed
13
Research Sites
116 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participants who: * Are children aged between 6 and less than 12 years old * Have had migraine for at least 6 months. * Weigh more than 15 kilograms All participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril). The dose of the study medicine that each participant receives will depend on how much the participant weighs. The study will look at the experiences of the participants receiving the study medicine and collect data to better understand the possible benefits and unwanted effects of different doses of the study medicine. Participants will take part in this study for up to 10 weeks. During this time, they will have 3 study visits at the study clinic, and 2 follow-up phone calls.
CONDITIONS
Official Title
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 6 years to less than 12 years
- History of migraine with or without aura for at least 6 months before screening
- Weight greater than 15 kilograms at screening
You will not qualify if you...
- History or evidence of clinically significant disease
- Continuous migraine within 1 month before screening
- Atypical migraine types or complicated migraine or significant pain syndromes
- Conditions affecting nasal spray administration or absorption
- Uncontrolled or untreated psychiatric conditions including significant depression or suicidal ideation
- Elevated liver enzymes or bilirubin above set limits
- Abnormal electrocardiogram at screening visit
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Arkansas Children's Hospital
Little Rock, Arkansas, United States, 72202
Not Yet Recruiting
2
Velocity Clinical Research, Washington DC
Washington D.C., District of Columbia, United States, 20016
Not Yet Recruiting
3
Coastal Heritage Clinical Research
Hinesville, Georgia, United States, 31313
Actively Recruiting
4
Clinical Research Institute
Minneapolis, Minnesota, United States, 55402
Not Yet Recruiting
5
Children's Hospital & Medical Center
Omaha, Nebraska, United States, 68114
Actively Recruiting
6
True North Neurology
Port Jefferson Station, New York, United States, 11776
Not Yet Recruiting
7
Accellacare - Piedmont
Statesville, North Carolina, United States, 28625
Actively Recruiting
8
Accellacare of Piedmont HealthCare
Statesville, North Carolina, United States, 28625
Actively Recruiting
9
Accellacare US Inc.
Winston-Salem, North Carolina, United States, 27103
Actively Recruiting
10
Central States Research
Tulsa, Oklahoma, United States, 74136
Actively Recruiting
11
Cedar Health Research
Dallas, Texas, United States, 75251
Actively Recruiting
12
Wasatch Clinical Research, LLC
Salt Lake City, Utah, United States, 84107
Actively Recruiting
13
Granger Medical Holladay - Holladay Clinic
Salt Lake City, Utah, United States, 84117
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here